Immunovia Balance Sheet Health

Financial Health criteria checks 4/6

Immunovia has a total shareholder equity of SEK38.6M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK63.1M and SEK24.5M respectively.

Key information

Debt to equity ratio

SEK 0

Debt

Interest coverage ratio	n/a
Cash	SEK 54.20m
Equity	SEK 38.60m
Total liabilities	SEK 24.50m
Total assets	SEK 63.10m

Recent financial health updates

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

Jan 18

We Think Immunovia (STO:IMMNOV) Can Afford To Drive Business Growth

Aug 28

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

Feb 03

Recent updates

Here's Why We're Watching Immunovia's (STO:IMMNOV) Cash Burn Situation

Apr 20

We're Keeping An Eye On Immunovia's (STO:IMMNOV) Cash Burn Rate

Dec 09

Is Immunovia (STO:IMMNOV) In A Good Position To Invest In Growth?

May 13

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

Jan 18

We Think Immunovia (STO:IMMNOV) Can Afford To Drive Business Growth

Aug 28

What Kind Of Investors Own Most Of Immunovia AB (publ) (STO:IMMNOV)?

Mar 09

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

Feb 03

Financial Position Analysis

Short Term Liabilities: IMMNOV's short term assets (SEK57.9M) exceed its short term liabilities (SEK24.5M).

Long Term Liabilities: IMMNOV has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: IMMNOV is debt free.

Reducing Debt: IMMNOV has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMMNOV has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IMMNOV has less than a year of cash runway if free cash flow continues to reduce at historical rates of 2.3% each year

Discover healthy companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/30 17:35
End of Day Share Price	2024/12/30 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Immunovia AB (publ) is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Lars Hevreng	Danske Bank
Juan Pedro Rodríguez Serrate	Edison Investment Research
Alexandru Cogut	Kempen & Co. NV

Immunovia Balance Sheet Health

Financial Health criteria checks 4/6

Key information

Recent financial health updates

Here's Why We're Watching Immunovia's (STO:IMMNOV) Cash Burn Situation

We're Keeping An Eye On Immunovia's (STO:IMMNOV) Cash Burn Rate

Is Immunovia (STO:IMMNOV) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

We Think Immunovia (STO:IMMNOV) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

Recent updates

Immunovia AB (publ), Annual General Meeting, May 14, 2025

Immunovia AB (publ) to Report Q3, 2025 Results on Nov 19, 2025

Immunovia AB (publ) Announces Positive Outcome and Strong Accuracy in the Clinical Validation of Its Next-Generation Test for Pancreatic Cancer

Third quarter 2024 earnings released: kr0.73 loss per share (vs kr0.91 loss in 3Q 2023)

Immunovia Presents Model-Development Study Results At Meeting of the Collaborative Group of the Americas-Inherited Gastrointestinal Cancers

Immunovia AB (Publ) Acquires All Blood Samples Required to Clinically Validate Its Next-Generation Test for Pancreatic Cancer

Immunovia Completes Analytical Validation of Its Next-Generation Pancreatic Cancer Test

New major risk - Shareholder dilution

New major risk - Shareholder dilution

Second quarter 2024 earnings released: kr0.56 loss per share (vs kr4.00 loss in 2Q 2023)

Immunovia AB (publ) Announces the Next-Generation Test to Be Included in Large Study of Pancreatic Cysts funded by the U.S. National Institutes of Health

Immunovia Files US Patent Application to Protect Its Next-Generation Test

Immunovia Completes Development of Its Pancreatic Cancer Detection Test After Substantially Increasing Test Accuracy

Immunovia AB Presents Detailed Discovery Study Results for its Next-Generation Early Detection Test for Pancreatic Cancer at PancreasFest 2024 Annual Meeting

Immunovia AB (publ) to Report Fiscal Year 2024 Results on Feb 25, 2025

Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina

Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test

Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study

Full year 2023 earnings released: kr7.95 loss per share (vs kr7.43 loss in FY 2022)

Immunovia AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Third quarter 2023 earnings released: kr0.91 loss per share (vs kr1.01 loss in 3Q 2022)

Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development

Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection

New major risk - Revenue and earnings growth

Immunovia AB (publ) Announces Board Changes

First quarter 2023 earnings released: kr2.28 loss per share (vs kr1.95 loss in 1Q 2022)

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're Watching Immunovia's (STO:IMMNOV) Cash Burn Situation

Forecast to breakeven in 2024

Immunovia Realigning Swedish Operations with Strategic Priorities and its Focus on the US Commercialization of the Immray Pancan-D Test

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

We're Keeping An Eye On Immunovia's (STO:IMMNOV) Cash Burn Rate

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Forecast to breakeven in 2024

Price target decreased to kr110

Immunovia AB (publ), Annual General Meeting, Apr 27, 2023

Immunovia AB (Publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

Immunovia AB Announces Executive Management Team Appointments

Immunovia AB Announces Positive Update on Physician Experience Program with IMMrayTM PanCan-d

Immunovia AB Issues Preliminary Payment Rate Determination for IMMray PanCan-D Test

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Immunovia, Inc. Receives Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray Pancan-d Test

Immunovia AB Announces PanDIA-1 Study for Early Detection of Pancreatic Cancer in Newly Onset Type Diabetics Moves into Next Phase

Immunovia AB Announces Results from PanFAM-1 Study

Immunovia AB (publ) Announces Executive Changes

Immunovia Names Philipp Mathieu as Chief Executive Officer

Immunovia AB Appoints Natalie Carfora as Head of Market Access US Subsidiary

Is Immunovia (STO:IMMNOV) In A Good Position To Invest In Growth?

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Immunovia AB (Publ) Announces Board Changes

Independent Director recently bought kr186k worth of stock

Price target decreased to kr215

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

Third quarter 2021 earnings released: kr1.60 loss per share (vs kr1.68 loss in 3Q 2020)

Price target increased to kr298

We Think Immunovia (STO:IMMNOV) Can Afford To Drive Business Growth

Second quarter 2021 earnings released: kr2.18 loss per share (vs kr1.67 loss in 2Q 2020)

Immunovia AB (publ) Receives Approval to Begin Testing Patients for Pancreatic Cancer with the Immrayt Pancan-D Test

Chief Executive Officer recently bought kr676k worth of stock

Price target increased to kr300

Independent Director recently bought kr298k worth of stock

Independent Director has left the company

Independent Director recently bought kr192k worth of stock

First quarter 2021 earnings released: kr1.04 loss per share (vs kr1.41 loss in 1Q 2020)